after joining the trial you will attend a baseline visit where weight, height, blood pressure and a blood sample are taken. these measurements create the starting point for later comparisons. you will also complete a health questionnaire. based on the random assignment you will receive either MET097 or a matching placebo.

the study medication is given as a subcutaneous injection, which means it is injected just under the skin.

within the first week you will receive the initial injection. the dose is the prepared solution of MET097 (5 mg/mL) administered once‑weekly. the same volume is used for the placebo.

you will inject the assigned product once every week for the duration of the study. injections are performed at the same time each week, using the same subcutaneous technique.

the weekly schedule continues until at least week 84, the final time point of the trial.

throughout the trial you will attend study visits at scheduled weeks, including week 12, week 24, week 36, week 48, week 64 and week 84. during each visit weight, blood glucose (HbA1c), blood lipids (triglycerides, non‑HDL cholesterol), and blood pressure are measured. you will also answer the Short Form 36 questionnaire that assesses physical function.

the primary efficacy assessment occurs at week 64, when the change in body weight is compared to the baseline value.

at week 84 a final evaluation is performed. the same measurements taken at earlier visits are repeated to determine the long‑term effect of the treatment on weight, blood sugar control and other health indicators.